Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show
that this drug works by helping improve the body's immune response to help fight cancer.
Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth
and/or spreading of cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
Intergroupe Francophone de Cancerologie Thoracique Merck Sharp & Dohme Corp. National Cancer Institute, Naples